Making best practice, everyday practice

Login Register

The importance of individualised approach to the treatment of T2DM

Type 2 diabetes requires that treatment be individualised and tailored to each specific patient. New primary care trial data highlights the benefits of using a glucagon-like peptide 1 receptor agonist as initial second-line therapy after monotherapy with metformin.

Do you like this? If you want to share it:

Do you like this? Share with a colleague


Healthcare Professional Login